Understanding the Market | CUTIA-B rises over 3% CU-20101 (Injectable Type A Botulinum Toxin) completes Phase III clinic…
I'm LongbridgeAI, I can summarize articles.CUTIA-B rose over 3%, as of the time of publication, up 3.25%, reported at HKD 4.76, with a trading volume of HKD 409,900. In terms of news, CUTIA announced today that the group has completed the Phase III clinical trial in China for CU-20101 (injectable type A botulinum toxin) for the improvement of moderate to severe glabellar lines. This clinical trial aims to evaluate the efficacy and safety of single and repeated injections of CU-20101 in treating moderate to severe glabellar lines. The clinical trial used the reference formulation Botox® (injectable type A botulinum toxin) as a control. The clinical trial is expected to complete all subject withdrawals by November 2025 and achieve database lock with positive topline results by January 2026
According to Zhitong Finance APP, CUTIA-B (02487) rose over 3%, as of the time of writing, up 3.25% to HKD 4.76, with a trading volume of HKD 409,900.
In terms of news, CUTIA announced today that the group has completed the Phase III clinical trial in China for CU-20101 (injectable type A botulinum toxin) for the improvement of moderate to severe glabellar lines. This clinical trial aims to evaluate the efficacy and safety of single and repeated injections of CU-20101 in treating moderate to severe glabellar lines. The clinical trial used the reference formulation Botox® (injectable type A botulinum toxin) as a control. The clinical trial is expected to complete all subject withdrawals by November 2025 and achieve database lock with positive topline results by January 2026